This 10% fluctuation has been more than 20- ) but I have bought more with each of these take downs.
jmho - but Genomic Health will be taken out before the Oco Dx for Prostate takes off because a buyer knows that will increase the takeover price considerably.
Steve Burrill is in Geneva and the outside the US operations are the under appreciated aspect of the company ...say nothing of the research arm headed by Baker.
A "ballpark" is of course speculation,and I have also speculated( I have talked to Kim and others,but do not pretend to be anything but an investor)........that Genomic Health may sell off a portion of the company in order to stay Research intensive single.... which I am sure what management wants....
ok that speculation over coffee out of the way,- ) a double is certainly within the realm., so we agree,the question is when? Good Luck